Semaglutide has become one of the most actively researched GLP-1 receptor agonists in preclinical and in vitro science. As a 31-amino-acid peptide analog of human glucagon-like peptide-1, semaglutide is distinguished by a C18 fatty acid chain conjugated via a linker to Lys26, which enables albumin binding and extends its circulating half-life in biological systems.
Access verified quality documentation and research-grade peptides.
View Certificates of Analysis Explore Research-Grade PeptidesDisclaimer: All compounds referenced in this article are intended for laboratory research use only. They are not approved for human or veterinary use by the FDA or any regulatory agency.